Total Payments
$994,066
2024 Payments
$111,243
Companies
98
Transactions
2,048
Medicare Patients
3,406
Medicare Billing
$587,289
Payment Breakdown by Category
Other$718,241 (72.3%)
Consulting$170,829 (17.2%)
Travel$64,654 (6.5%)
Food & Beverage$39,981 (4.0%)
Education$360.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $679,640 | 275 | 68.4% |
| Consulting Fee | $170,829 | 82 | 17.2% |
| Travel and Lodging | $64,654 | 187 | 6.5% |
| Food and Beverage | $39,981 | 1,469 | 4.0% |
| Honoraria | $38,601 | 23 | 3.9% |
| Education | $360.75 | 12 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $140,552 | 176 | $0 (2024) |
| Incyte Corporation | $123,564 | 126 | $0 (2024) |
| Celgene Corporation | $116,729 | 141 | $0 (2024) |
| ABBVIE INC. | $105,642 | 139 | $0 (2024) |
| BeiGene USA, Inc. | $78,760 | 67 | $0 (2024) |
| Lilly USA, LLC | $65,073 | 66 | $0 (2024) |
| Gilead Sciences, Inc. | $46,910 | 59 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $41,104 | 86 | $0 (2024) |
| Genentech USA, Inc. | $36,274 | 124 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $33,215 | 37 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,243 | 237 | BeiGene USA, Inc. ($27,942) |
| 2023 | $152,874 | 210 | Lilly USA, LLC ($35,693) |
| 2022 | $127,165 | 144 | BeiGene USA, Inc. ($19,031) |
| 2021 | $101,969 | 191 | Incyte Corporation ($22,597) |
| 2020 | $119,028 | 274 | Celgene Corporation ($38,093) |
| 2019 | $189,951 | 373 | AbbVie, Inc. ($45,341) |
| 2018 | $131,373 | 369 | Gilead Sciences, Inc. ($28,747) |
| 2017 | $60,464 | 250 | Celgene Corporation ($17,178) |
All Payment Transactions
2,048 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $8.78 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.44 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.68 | General |
| 12/16/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/08/2024 | Genentech, Inc. | Columvi (Biological), Polivy | Food and Beverage | In-kind items and services | $73.63 | General |
| Category: BioOncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Oncology | ||||||
| 12/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $33.14 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 12/02/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $50.00 | General |
| 12/02/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Genetically Defined Disease | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,750.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $727.94 | General |
| Category: Oncology | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $593.94 | General |
| Category: Oncology | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $176.03 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 820 | 1,580 | $505,020 | $150,330 |
| 2022 | 10 | 732 | 1,423 | $485,290 | $140,538 |
| 2021 | 13 | 856 | 1,693 | $505,201 | $149,929 |
| 2020 | 14 | 998 | 2,169 | $484,072 | $146,492 |
Total Patients
3,406
Total Services
6,865
Medicare Billing
$587,289
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 290 | 663 | $232,249 | $67,213 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 152 | 338 | $166,053 | $48,953 | 29.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 110 | $29,615 | $10,782 | 36.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 59 | 59 | $35,290 | $9,999 | 28.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 29 | $15,095 | $4,144 | 27.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 22 | 28 | $9,808 | $2,919 | 29.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 40 | 40 | $7,649 | $2,874 | 37.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 139 | 271 | $7,371 | $2,062 | 28.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 42 | 42 | $1,890 | $1,383 | 73.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 315 | 783 | $274,326 | $77,813 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 119 | 186 | $91,376 | $27,586 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 142 | $38,242 | $12,020 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 61 | 61 | $36,467 | $10,617 | 29.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 49 | 56 | $19,629 | $4,849 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $9,888 | $2,958 | 29.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 23 | 24 | $4,568 | $1,642 | 35.9% |
| 36430 | Transfusion of blood or blood products | Office | 2022 | 18 | 48 | $7,520 | $1,634 | 21.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 24 | 25 | $1,125 | $815.67 | 72.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 54 | 79 | $2,149 | $605.51 | 28.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 313 | 858 | $299,630 | $88,865 | 29.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 85 | 147 | $71,574 | $22,316 | 31.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 71 | 71 | $41,916 | $12,048 | 28.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 43 | 98 | $26,234 | $8,451 | 32.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 62 | 79 | $27,337 | $7,177 | 26.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $14,096 | $4,522 | 32.1% |
About Dr. Marin Xavier, MD
Dr. Marin Xavier, MD is a Hematology & Oncology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437211372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marin Xavier, MD has received a total of $994,066 in payments from pharmaceutical and medical device companies, with $111,243 received in 2024. These payments were reported across 2,048 transactions from 98 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($679,640).
As a Medicare-enrolled provider, Xavier has provided services to 3,406 Medicare beneficiaries, totaling 6,865 services with total Medicare billing of $587,289. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location San Diego, CA
- Active Since 12/15/2006
- Last Updated 01/02/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437211372
Products in Payments
- CALQUENCE (Drug) $135,994
- BRUKINSA (Drug) $77,635
- JAKAFI (Drug) $62,804
- Venclexta (Drug) $54,246
- REBLOZYL (Biological) $53,967
- Revlimid (Drug) $49,964
- MONJUVI (Drug) $41,187
- ADCETRIS (Biological) $38,887
- VENCLEXTA (Drug) $32,031
- NINLARO (Drug) $31,967
- VENCLEXTA (Biological) $31,144
- Zydelig (Drug) $21,117
- INREBIC (Drug) $18,349
- JAYPIRCA (Drug) $15,748
- Yescarta (Drug) $13,805
- Inrebic (Drug) $13,221
- Epkinly (Drug) $12,557
- TAZVERIK (Drug) $11,766
- XOSPATA (Drug) $10,498
- IMBRUVICA (Drug) $8,862
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Diego
Wendy Levin, Md, MD
Hematology & Oncology — Payments: $2.1M
Hematology & Oncology $2.1M
Ezra Cohen, Md, MD
Hematology & Oncology — Payments: $744,736
Hematology & Oncology $744,736
Rana Mckay, Md, MD
Hematology & Oncology — Payments: $462,907
Hematology & Oncology $462,907
Dr. Annette Von Drygalski, Md, MD
Hematology & Oncology — Payments: $412,692
Hematology & Oncology $412,692
Dr. Lyudmila Bazhenova, M.d, M.D
Hematology & Oncology — Payments: $392,037
Hematology & Oncology $392,037
Dr. Sandip Patel, M.d, M.D
Hematology & Oncology — Payments: $313,568
Hematology & Oncology $313,568